Blog dedicated to the continuous education in Gynecology and Endocrinology

 

ANGELIQ VERSUS ACTIVELLE IN NORMOTENSIVE POSTMENOPAUSAL WOMEN: A PROSPECTIVE, RANDOMIZED PILOT STUDY

5) Menopause. 2009 Jul-Aug;16(4):803-9

Battaglia C, Cianciosi A, Mancini F, Persico N, Sisti G, Facchinetti F, Busacchi P.

OBJECTIVE: The aim of this study was to compare, in normotensive postmenopausal women, the effects of drospirenone/estradiol and norethisterone acetate/estradiol on blood pressure and other surrogate markers of cerebrovascular and cardiovascular risk. more

Post to Twitter Post to Facebook

THE ASSOCIATION BETWEEN ONION CONSUMPTION AND BONE DENSITY IN PERIMENOPAUSAL AND POSTMENOPAUSAL NON-HISPANIC WHITE WOMEN 50 YEARS AND OLDER

2) Menopause. 2009 Jul-Aug;16(4):756-9

Matheson EM, Mainous AG 3rd, Carnemolla MA.

OBJECTIVE: The aim of this study was to determine whether frequent onion consumption is associated with increased bone density in perimenopausal and postmenopausal non-Hispanic white women 50 years and older. METHODS: An analysis of the National Health and Nutrition Examination Survey 2003-2004 was performed. more

Post to Twitter Post to Facebook

• July, 2009 •

Tibolone revisited: Still a good treatment option for healthy, early postmenopausal women.

Peter Kenemans

Tibolone is a synthetic steroid that has, through its metabolites, specific effects in different tissues, due to tissue-selective enzyme regulation and steroid receptor activation. At present it is widely used throughout the world for the reduction of menopausal complaints in early postmenopausal women. It has been registered in 90 countries for the treatment of climacteric symptoms and in 55 countries for the prevention of osteoporosis.

Tibolone is taken as one tablet of 2.5 mg daily. After oral intake, tibolone is converted into 3 active metabolites, 2 of which have estrogenic effects, while 1, the delta-4 isomer, has both progestogenic and androgenic properties. Due to its unique mode of action, tibolone has been classified as a selective tissue estrogenic activity regulator, a STEAR (1). more

Post to Twitter Post to Facebook

Menopausal hot flush: is it a nuisance or a marker of cardiovascular disease risk?

Prelevic

Hot flush is one of the most commonly reported symptoms during menopause, however, it is not experienced by all menopausal women, for reasons that remain unclear. In this review we present current evidence that link hot flushes with cardiovascular disease, suggesting that the persistence of hot flushes many years after the menopause may represent a marker of an underlying disorder that increases the risk for cardiovascular disease.

Post to Twitter Post to Facebook

Long-term oral contraceptive treatment, metabolic syndrome and measures of cardiovascular risk in pre-menopausal Women: national health and nutrition examination survey 1999-2004.

Hurwitz

Aim. Differences in subclinical cardiometabolic measures were examined as a function of oral contraceptive pills (OCP) treatment duration to compare never-treated women with four OCP-treatment groups (<1, 1 5, 5 10, and >10 yrs). more

Post to Twitter Post to Facebook

© International Society of Gynecological Endocrinology - Privacy Policy